Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.
2.

Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Haddad PM, Wieck A.

Drugs. 2004;64(20):2291-314. Review.

PMID:
15456328
3.

Antipsychotic-induced hyperprolactinemia.

Bostwick JR, Guthrie SK, Ellingrod VL.

Pharmacotherapy. 2009 Jan;29(1):64-73. doi: 10.1592/phco.29.1.64. Review.

4.

Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists.

Holt RI.

J Psychopharmacol. 2008 Mar;22(2 Suppl):28-37. doi: 10.1177/0269881107087951. Review.

PMID:
18477618
5.

[Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].

Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C.

Encephale. 2014 Feb;40(1):86-94. doi: 10.1016/j.encep.2012.03.002. Epub 2013 Aug 5. Review. French.

PMID:
23928066
6.

The evolution of hyperprolactinaemia as an entity in psychiatric patients.

Kohen D, Wildgust HJ.

J Psychopharmacol. 2008 Mar;22(2 Suppl):6-11. doi: 10.1177/0269216307087147. Review.

PMID:
18477616
7.

Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.

O'Keane V.

J Psychopharmacol. 2008 Mar;22(2 Suppl):70-5. doi: 10.1177/0269881107088439. Review.

PMID:
18477623
8.

Hyperprolactinaemia and antipsychotic therapy in schizophrenia.

Hummer M, Huber J.

Curr Med Res Opin. 2004;20(2):189-97. Review.

PMID:
15006013
9.

Antipsychotic-induced hyperprolactinaemia.

Inder WJ, Castle D.

Aust N Z J Psychiatry. 2011 Oct;45(10):830-7. doi: 10.3109/00048674.2011.589044. Epub 2011 Jun 30. Review.

PMID:
21714721
10.

[Antipsychotics and hyperpolactinaemia: pathophysiology, clinical relevance, diagnosis and therapy].

Riecher-Rössler A, Schmid C, Bleuer S, Birkhäuser M.

Neuropsychiatr. 2009;23(2):71-83. German.

PMID:
19573500
11.

Prolactin awareness: an essential consideration for physical health in schizophrenia.

Montejo AL.

Eur Neuropsychopharmacol. 2008 May;18 Suppl 2:S108-14. doi: 10.1016/j.euroneuro.2008.02.004. Review.

PMID:
18346598
12.

A review of the association between antipsychotic use and hyperprolactinaemia.

Bushe C, Shaw M, Peveler RC.

J Psychopharmacol. 2008 Mar;22(2 Suppl):46-55. doi: 10.1177/0269881107088435. Review.

PMID:
18477620
13.

The impact of hyperprolactinaemia on sexual function in patients with psychosis.

Smith SM.

J Psychopharmacol. 2008 Mar;22(2 Suppl):63-9. doi: 10.1177/0269881107088438. Review.

PMID:
18477622
14.
15.

[Hyperprolactinemia in mentally ill patients].

Carvalho MM, Góis C.

Acta Med Port. 2011 Nov-Dec;24(6):1005-12. Epub 2012 Feb 20. Review. Portuguese.

16.

Antipsychotic-induced hyperprolactinemia and sexual dysfunction.

Compton MT, Miller AH.

Psychopharmacol Bull. 2002 Winter;36(1):143-64. Review.

PMID:
12397853
17.

A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry?

Bushe CJ, Bradley A, Pendlebury J.

Ann Clin Biochem. 2010 Jul;47(Pt 4):292-300. doi: 10.1258/acb.2010.010025. Review.

PMID:
20592331
18.

Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis.

Cookson J, Hodgson R, Wildgust HJ.

J Psychopharmacol. 2012 May;26(5 Suppl):42-51. doi: 10.1177/0269881112442016. Epub 2012 Apr 2. Review.

PMID:
22472310
19.

Sexual dysfunction in schizophrenia: focus on recent evidence.

Baggaley M.

Hum Psychopharmacol. 2008 Apr;23(3):201-9. doi: 10.1002/hup.924. Review.

PMID:
18338766
20.

Effects of antipsychotics on sexual and endocrine function in women: implications for clinical practice.

Smith S.

J Clin Psychopharmacol. 2003 Jun;23(3 Suppl 1):S27-32. Review.

PMID:
12832947

Supplemental Content

Support Center